

K083627
pg 1 of 2

SECTION 5
510(k) SUMMARY

510(k) SUMMARY

1. Submitter:

APR - 7 2009

Boston Scientific Corporation
100 Boston Scientific Way
Marlborough, MA 01760
Telephone: 508-683-4454
Fax: 508-683-5939

Contact: Marybeth Gamber
Manager, Regulatory Affairs
Date Prepared: December 5, 2008

2. Device:

Trade Name: WallFlex® Biliary RX Fully Covered Stent System
Common Name: Biliary Stent
Classification Name: Biliary Catheter and Accessories
Regulation Number: 876.5010
Product Code: FGE
Classification: Class II

3. Predicate Device:

WallStent™ RX Biliary Endoprosthesis	K012752, K030107
Manufactured by Boston Scientific, Inc.	
WallFlex® Biliary RX Stent System	K061231
Manufactured by Boston Scientific, Inc.	

4. Device Description:

The WallFlex Biliary RX Fully Covered Stent System consists of a self-expanding metal stent and a delivery system. The stent is fully covered with Permalume coating and includes a retrieval loop at the proximal end of the stent to aid in removal during the initial stent placement procedure. The stent is mounted onto a sheath delivery system. The delivery system is a coaxial tubing assembly that constrains the stent onto the delivery system shaft until the stent is released by retracting the exterior tube.

000010

5. Intended Use:

The WallFlex Biliary RX Fully Covered Stent System is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms.

6. Technological Characteristics:

The WallFlex Biliary RX Fully Covered Stent System has the same technological characteristics as the currently marketed WallFlex Biliary RX Uncovered Stent System (K061231) and the Wallstent™ RX Biliary Endoprosthesis (K012752, K030107).

7. Performance Data:

In-vitro, *in-vivo*, and clinical testing have been performed, and all components, subassemblies, and/or full devices met the required specifications for the completed tests.

8. Conclusion:

Boston Scientific Corporation has demonstrated that the proposed WallFlex Biliary RX Fully Covered Stent System is substantially equivalent to Boston Scientific Corporation's currently marketed WallFlex Biliary RX Stent System (K061231) and Wallstent RX Biliary Endoprosthesis (K012752, K030107).



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Marybeth Gamber
Manager, Regulatory Affairs
Boston Scientific Corporation
100 Boston Scientific Way
MARLBOROUGH MA 01752

APR - 7 2009

Re: K083627
Trade/Device Name: WallFlex® Biliary RX Fully Covered Stent System
Regulation Number: 21 CFR §876.5010
Regulation Name: Biliary catheter and accessories
Regulatory Class: II
Product Code: FGE
Dated: March 16, 2009
Received: March 31, 2009

Dear Ms. Gamber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.

The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Donna-Bea Tillman, Ph.D., M.P.A.
Director
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

SECTION 4
INDICATIONS FOR USE STATEMENT

510(k) Number (if known): ~~This application~~ K083627


Device Name: WallFlex® Biliary RX Fully Covered Stent System

Indications for Use: The WallFlex Biliary RX Fully Covered Stent System is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Prescription Use X AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number K083627